Uploaded September 2026 | Updated November 2026, 2 days ago
What does “treatment” really mean when an eye disease can lead to blindness if left untreated? This video highlights how innovation in ophthalmology begins with listening closely to patients and physicians to better understand unmet medical needs.
From there, teams work to translate those insights into meaningful solutions—prioritizing durability (so patients may need fewer injections) and designing delivery devices for simplicity and precision, because streamlined steps can support efficient drug delivery.
In this video, you’ll hear about:
- Why unmet medical need is the starting point for innovation
- How patient and physician insights inform research and development
- What “durability” can mean in treatment design (including fewer injections)
- Why precision and simplicity matter in drug delivery
At Bayer, we are committed to advancing ophthalmology research to help address serious eye diseases and support patients and their healthcare teams.
What does “treatment” really mean when an eye disease can lead to blindness if left untreated? This video highlights how innovation in ophthalmology begins with listening closely to patients and physicians to better understand unmet medical needs.
From there, teams work to translate those insights into meaningful solutions—prioritizing durability (so patients may need fewer injections) and designing delivery devices for simplicity and precision, because streamlined steps can support efficient drug delivery.
In this video, you’ll hear about:
- Why unmet medical need is the starting point for innovation
- How patient and physician insights inform research and development
- What “durability” can mean in treatment design (including fewer injections)
- Why precision and simplicity matter in drug delivery
At Bayer, we are committed to advancing ophthalmology research to help address serious eye diseases and support patients and their healthcare teams.










